Panzyga (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Panzyga, is an immunoglobulin presented as a sterile intravenous solution for infusion use. It is used to replace deficient antibodies in patients with primary or secondary immunodeficiency disorders and to modulate immune responses in certain autoimmune conditions. GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Panzyga is an immunoglobulin therapy that acts on the humoral immune system to restore antibody levels in various deficiency and immune‑mediated conditions. - Primary Immunodeficiency (PID): replaces missing antibodies, reducing the frequency and severity of infections. - Immune Thrombocytopenic Purpura (ITP): modulates the immune response, helping to increase platelet counts. - Chronic Lymphocytic Leukemia‑associated hypogammaglobulinemia: supports immune function in patients with low IgG levels. - Secondary immunodeficiency after hematopoietic stem‑cell transplantation: provides passive immunity during immune reconstitution.

Panzyga may be associated with a range of adverse reactions, most of which are related to the infusion process or immune modulation.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever and chills: typical infusion‑related symptoms. - Nausea or vomiting: usually mild and self‑limiting. - Fatigue: generalized tiredness during or after infusion. - Infusion site reactions: erythema, swelling, or discomfort at the catheter site. - Hypertension: temporary elevation of blood pressure.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Thromboembolic events: clot formation in veins or arteries. - Renal dysfunction: acute kidney injury, especially with rapid infusion. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells. - Severe hypotension: marked drop in blood pressure requiring intervention.

Prior to initiating Panzyga therapy, clinicians should consider several safety measures to minimise risks. - Screening: assess baseline IgG levels and screen for anti‑IgA antibodies in IgA‑deficient patients. - Monitoring: observe patients closely during the first infusion for signs of reaction. - Contraindications: avoid use in individuals with known severe IgA deficiency and anti‑IgA antibodies. - Pregnancy: prescribe only if the potential benefit justifies potential fetal risk. - Breastfeeding: exercise caution; weigh maternal benefit against possible infant exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Panzyga can interact with other therapies, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may be less effective due to immune modulation. - Immunosuppressants (e.g., high‑dose steroids): increase infection risk when combined. - Anticoagulants: heightened risk of thrombotic complications.

Moderate Interactions (Monitor Closely): - ACE inhibitors: potential additive hypotensive effect. - Diuretics: monitor renal function and electrolytes. - Cytotoxic chemotherapy: may exacerbate immunosuppression, requiring dose adjustments.